Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. At this time, I would like to welcome everyone to Sirius Therapeutics' second quarter 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press the star 1. Thank you. I would now like to turn the conference over to Dr. Carlo Tanzi, Investor Relations. Please go ahead. Thank you and good morning. Our press release with the company's second quarter 2024 financial results and a business update became available at 7 a.m. Eastern Time this morning and can be found on the Investors & You section of the company's website. The company has also posted an updated corporate presentation to the website. I'd like to remind you that we'll be making forward-looking statements, including related to the financial terms, timing, and completion of the sale of VALS assets to Nestle Health Science, the receipt of future payments and the use of proceeds of the transaction, the timing and results of clinical studies and data readouts, development plans and commercial opportunities, operating plans and our future cash runway, are planned strategic focus and other statements which are not historical fact. Actual results may differ materially. On today's call with prepared remarks, I'm joined by Eric Schaaf, CERE's President and CEO, Mirela Thorell, CFO, Dr. Lisa Von Mulkey, Chief Medical Officer, Dr. Matthew Henn, Chief Scientific Officer, and Dr. Terry Young, Chief Commercial and Strategy Officer. With that, I'll pass the call to Eric. Thank you, Carlo, and g...